Abstract：
OBJECTIVE: We investigated metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on pre-treatment FDG-PET as prognostic markers for survival in patients with metastatic neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT).
METHODS: A retrospective review of patients with metastatic NENs receiving PRRT was undertaken. Pre-treatment FDG-PET images were analyzed and variables collected included MTV and TLG (dichotomized by median into high vs low). Main Outcomes were overall survival (OS) and progression-free survival (PFS) by MTV and TLG (high vs low).
RESULTS: One hundred five patients were included. Median age was 64 years (50% male). Main primary NEN sites were small bowel (43.8%) and pancreas (40.0%). Median MTV was 3.8 mL and median TLG was 19.9. Dichotomization formed identical cohorts regardless of whether MTV or TLG were used. Median OS was 72 months; OS did not differ based on MTV/TLG high versus low (47.4 months vs not reached; hazard ratio, 0.43; 95% confidence interval [CI], 0.18-1.04; P = 0.0594). Median PFS was 30.4 months; PFS differed based on MTV/TLG high versus low (21.6 months vs 45.7 months; hazard ratio, 0.35; 95% CI, 0.19-0.64; P = 0.007).
CONCLUSIONS: Low MTV/TLG on pre-treatment FDG-PET was associated with longer PFS in metastatic NEN patients receiving PRRT.
METHODS: A retrospective review of patients with metastatic NENs receiving PRRT was undertaken. Pre-treatment FDG-PET images were analyzed and variables collected included MTV and TLG (dichotomized by median into high vs low). Main Outcomes were overall survival (OS) and progression-free survival (PFS) by MTV and TLG (high vs low).
RESULTS: One hundred five patients were included. Median age was 64 years (50% male). Main primary NEN sites were small bowel (43.8%) and pancreas (40.0%). Median MTV was 3.8 mL and median TLG was 19.9. Dichotomization formed identical cohorts regardless of whether MTV or TLG were used. Median OS was 72 months; OS did not differ based on MTV/TLG high versus low (47.4 months vs not reached; hazard ratio, 0.43; 95% confidence interval [CI], 0.18-1.04; P = 0.0594). Median PFS was 30.4 months; PFS differed based on MTV/TLG high versus low (21.6 months vs 45.7 months; hazard ratio, 0.35; 95% CI, 0.19-0.64; P = 0.007).
CONCLUSIONS: Low MTV/TLG on pre-treatment FDG-PET was associated with longer PFS in metastatic NEN patients receiving PRRT.
摘要：
目的：我们研究了接受肽受体放射性核素治疗的转移性神经内分泌肿瘤（NENs）患者治疗前FDG-PET的代谢肿瘤体积（MTV）和总病变糖酵解（TLG）作为生存的预后指标（PRRT）。
方法：对接受PRRT的转移性NENs患者进行回顾性分析。分析治疗前的FDG-PET图像，收集的变量包括MTV和TLG（由中位数分为高和低）。主要结果是MTV和TLG的总生存期（OS）和无进展生存期（PFS）（高与低）。
结果：纳入了105名患者。中位年龄为64岁（50%为男性）。主要NEN部位为小肠(43.8%)和胰腺(40.0%)。MTV中位数为3.8mL，TLG中位数为19.9。无论是否使用MTV或TLG，二分法都形成相同的队列。中位OS为72个月；OS根据MTV/TLG高与低（47.4个月与未达到；风险比，0.43；95%置信区间[CI]，0.18-1.04；P=0.0594）。PFS中位数为30.4个月；PFS基于MTV/TLG高与低（21.6个月与45.7个月；风险比，0.35；95%CI，0.19-0.64；P=0.007）。
结论：在接受PRRT的转移性NEN患者中，治疗前FDG-PET的MTV/TLG低与PFS延长相关。
方法：对接受PRRT的转移性NENs患者进行回顾性分析。分析治疗前的FDG-PET图像，收集的变量包括MTV和TLG（由中位数分为高和低）。主要结果是MTV和TLG的总生存期（OS）和无进展生存期（PFS）（高与低）。
结果：纳入了105名患者。中位年龄为64岁（50%为男性）。主要NEN部位为小肠(43.8%)和胰腺(40.0%)。MTV中位数为3.8mL，TLG中位数为19.9。无论是否使用MTV或TLG，二分法都形成相同的队列。中位OS为72个月；OS根据MTV/TLG高与低（47.4个月与未达到；风险比，0.43；95%置信区间[CI]，0.18-1.04；P=0.0594）。PFS中位数为30.4个月；PFS基于MTV/TLG高与低（21.6个月与45.7个月；风险比，0.35；95%CI，0.19-0.64；P=0.007）。
结论：在接受PRRT的转移性NEN患者中，治疗前FDG-PET的MTV/TLG低与PFS延长相关。
